Advances in rheumatology at the beginning of the 21st century

Насонов, Е. Л.; Лила, А. М.; Дубинина, Т. В.; Nikitinskaya, O. A.; Amirjanova, V. N.

doi:10.47360/1995-4484-2022-5-20

Naučno-praktičeskaâ revmatologiâ

2022

DOI: 10.47360/1995-4484-2022-5-20

|View full text |Cite

Advances in rheumatology at the beginning of the 21st century

Е. Л. Насонов

А. М. Лила

Т. В. Дубинина³

et al.

Abstract: .

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study

Karateev,

Polishchuk,

Filatova

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

AimEvaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real‐world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.MethodsAn open‐label observational non‐interventional study was conducted, enrolling 183 patients with moderate and severe RA activity. All patients received OKZ 64 mg SC as injections every 4 weeks (Q4W) with methotrexate. The patients' follow‐up period was 24 weeks or less. RA activity (DAS28‐CRP), pain severity (NRS), patient global assessment (PGA, NRS), functional impairment (NRS), fatigue (FACIT‐F), central sensitization (central sensitization inventory, CSI), and symptoms of neuropathic pain (PainDETECT) were evaluated.ResultsThe study cohort was comprised of 144 patients. And 39 patients were lost to follow‐up, refused OKZ treatment, or were not dosed with OKZ for administrative reasons. In 6 months, DAS28‐CRP decreased to 3.3 ± 0.9 (p < .001) and statistically significant reductions in pain intensity, PGA, functional impairment, and fatigue were achieved. Pain intensity decreased as early as 2 days after the first OKZ administration (p < .05). The number of patients with CSI >40 in 24 weeks decreased from 71.0% to 21.0% (p < .001), with PainDETECT >18 – from 21.5% to 13.2%. NSAIDs use decreased from 70.8% to 33.8% (р < .001), steroids – from 54.2% to 32.6%. AEs were reported in 14.2% patients, serious events were observed in three patients.ConclusionOKZ is effective in reducing RA activity and controlling chronic pain related to dysfunction of the nociceptive system.

show abstract

Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study

Karateev,

Polishchuk,

Filatova

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases

Bogatyreva,

Gerasimova,

Kirichenko

et al. 2024

Dokl Biochem Biophys

View full text Add to dashboard Cite

Possibilities of transposition of the extensores carpi tendons in the treatment of the rheumatoid hand

Rozov,

Byalik,

Lila

2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

With the advent of more effective conservative methods of treating rheumatoid arthritis (RA), patients with severe hand deformities are being treated less and less by orthopaedic surgeons. However, when significant changes occur in the hand joints, surgery is the only method to restore their function. The previously widespread arthrodesis procedures are gradually giving way to modern soft tissue joint-preserving surgeries that prevent the development of severe deformities and preserve hand function.Objective: to compare the functional outcomes of extensor carpi ulnaris and extensor carpi radialis longus transposition surgery (ECU+ECRL) and wrist joint arthrodesis in patients with RA.Material and methods. The study included 58 patients with a confirmed diagnosis of RA. Most patients (93%) were women with a disease duration of 4 to 6 years, the mean age was 46.3±14.6 years. All patients were seropositive for rheumatoid factors, most had radiological stages III and IV of RA according to Steinbrocker, radiological stage IV according to Larsen. Most of the patients had moderate disease activity. From 2021 to 2023, 21 patients underwent ECU + ECRL surgery and 37 patients underwent arthrodesis of the wrist joint. The groups were comparable in terms of key clinical characteristics. The average follow-up time after surgery was 6 months.Results and discussion. The mean DASH score in the transposition group (ECU + ECRL) was 38.3±10.12, while in the arthrodesis group it was 47.45±16.92 (p <0.05). In the late postoperative period (after 6 months), all patients showed a positive dynamics according to the visual analogue scale, which was comparable in both groups: in the ECU + ECRL group – 2.66±1.49 cm, in the arthrodesis group – 3.0±1.6 cm. The range of motion of the wrist was significantly greater in the ECU + ECRL group than in the arthrodesis group (p <0.05). At the follow-up examination in the postoperative period, a significant improvement in quality of life according to the EQ-5D was found in both the ECU+ECRL group (0.686) and the arthrodesis group (0.625), p<0.05.Conclusion. X-shaped extensor tendon plastic surgery for wrist joint stabilization should be considered a promising technique that can reduce pain and improve patients' functional status and quality of life.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Advances in rheumatology at the beginning of the 21st century

Abstract: .

Cited by 6 publications

References 141 publications

Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study

Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study

Proinflammatory Activation of Monocytes in Patients with Immunoinflammatory Rheumatic Diseases

Possibilities of transposition of the extensores carpi tendons in the treatment of the rheumatoid hand

Contact Info

Product

Resources

About